Cengent Therapeutics Overview
- Year Founded
-
2003

- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Financing Rounds
-
2
- Investments
-
1
Cengent Therapeutics General Information
Description
Operator of a drug discovery company. The company provides a suite of services and capabilities to optimize the drug discovery process and provides technologies such as homology modeling, X-ray crystallography and nuclear magnetic resonance (NMR) .
Contact Information
Corporate Office
- 10929 Technology Place
- San Diego, CA 92127
- United States
Corporate Office
- 10929 Technology Place
- San Diego, CA 92127
- United States
Cengent Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Cengent Therapeutics Patents
Cengent Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20080070867-A1 | 3-[3-bromo-4-(difluoro-phosphono-methyl)-benzyl]-4-(4-methanesulfonyl-phenyl)-2-oxo-2,3-dihydro-imidazole-1-carboxylic acid ethyl ester; diabetes, kidney failure, atherosclerosis, neurodegenerative diseases , obesity, cancer | Inactive | 19-Jan-2005 | ||
US-7381736-B2 | N-(4-{2-[[3-bromo-4-(difluoro-phosphono-methyl)-benzyl]-(3 ,4-dichloro-phenyl)-amino]-thiazol-4-yl}-phenyl)-oxalamic acid; antidiabetic, hypotensive agent; ischemia, kidney failure, atherosclerosis, metabolic syndrome, insulin resistance, leptin resistance, obesity, neurodegenerative diseases | Inactive | 02-Sep-2004 | ||
US-20060194768-A1 | N-(4-{2-[[3-bromo-4-(difluoro-phosphono-methyl)-benzyl]-(3 ,4-dichloro-phenyl)-amino]-thiazol-4-yl}-phenyl)-oxalamic acid; antidiabetic, hypotensive agent; ischemia, kidney failure, atherosclerosis, metabolic syndrome, insulin resistance, leptin resistance, obesity, neurodegenerative diseases | Active | 02-Sep-2004 | ||
US-20060135483-A1 | Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases | Inactive | 09-Jul-2004 | ||
US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | Inactive | 17-Jun-2004 | A61K31/66 |
Cengent Therapeutics Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Cengent Therapeutics Acquisitions (1)
Cengent Therapeutics’s most recent deal was a Merger/Acquisition with GeneFormatics. The deal was made on 19-May-2003.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
GeneFormatics | 19-May-2003 | Merger/Acquisition | Biotechnology |
Cengent Therapeutics FAQs
-
When was Cengent Therapeutics founded?
Cengent Therapeutics was founded in 2003.
-
Where is Cengent Therapeutics headquartered?
Cengent Therapeutics is headquartered in San Diego, CA.
-
What industry is Cengent Therapeutics in?
Cengent Therapeutics’s primary industry is Drug Discovery.
-
Is Cengent Therapeutics a private or public company?
Cengent Therapeutics is a Private company.
-
What is Cengent Therapeutics’s current revenue?
The current revenue for Cengent Therapeutics is
. -
Who are Cengent Therapeutics’s investors?
Aisling Capital, Burrill & Co, DKA Capital, IngleWood Ventures, and Ironbark Asset Management Fund Services are 5 of 10 investors who have invested in Cengent Therapeutics.
-
When was Cengent Therapeutics acquired?
Cengent Therapeutics was acquired on 27-Jun-2006.
-
Who acquired Cengent Therapeutics?
Cengent Therapeutics was acquired by Metabasis Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »